Bayer strikes deal with Atara Biotherapeutics to jointly work on CAR-T cell anti-tumour treatments
Frankfurt: Bayer AG has struck a deal with Atara Biotherapeutics to jointly work on Atara's CAR-T cell anti-tumour treatments, as the German group firms up its commitment to build a specialist cell and gene therapy development platform.
The deal to develop experimental mesothelioma treatments comes after Bayer said last week it was setting up a unit within its healthcare division to speed up and support cell and gene therapy development after recent takeovers.
With the agreement, the German drugmaker will get access to Atara's CAR T-cell therapy for solid tumours, ATA3271, which had shown anti-tumour activity in a pre-clinical study, as well as another treatment called ATA2271.
Bayer said it would make an upfront payment of $60 million to Atara and may also pay up to $610 million upon achievement of certain milestones, as well as tiered royalties up to a low double-digit percentage of net sales.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.